Ambrx Biopharma

General Information
Business:

We are a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs), using our proprietary expanded genetic code technology platform that allows us to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells. Our product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and efficacy benefits to treat patients across multiple therapeutic areas. We believe that our technology allows us to engineer a single optimized structure by designing the conjugation chemistries, selecting the precise number of amino acids and conjugation positions in the protein, and expanding the types of payloads that can be conjugated. 

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 70
Founded: 2003
Contact Information
Address 10975 North Torrey Pines Road, La Jolla, CA 92037, USA
Phone Number (858) 875-2400
Web Address http://www.ambrx.com
View Prospectus: Ambrx Biopharma
Financial Information
Market Cap
Revenues $13.7 mil (last 12 months)
Net Income $-16.5 mil (last 12 months)
IPO Profile
Symbol AMAM
Exchange NYSE
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Goldman Sachs/ BofA Securities/ Cowen
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change